Thermo Fisher Scientific Debuts Innovation?s in Bioprocess?ing at INTERPHEX 2014
Thermo Fisher Scientific Inc., the world leader in serving science, has introduced new innovations in cell culture and bioprocessing technologies to address the evolving requirements of biologic drug discovery and production for global biopharmaceutical and pharmaceutical manufacturers. These advancements, including a new high-volume centrifugation system and controller platforms for its next-generation single-use bioreactor, will be showcased this week at INTERPHEX, Jacob Javitz Convention Center, New York City, 18–20 March 2014, Booth #3544.
“Thermo Fisher has combined exceptional technologies with a deep understanding of the challenges of bringing biologic pharmaceuticals from discovery to development and production,” said Cory Stevenson, president of the bioprocessing business at Thermo Fisher. “The combination of Thermo Scientific single-use technologies with the cell culture, purification, and analytics capabilities under the Life Technologies brand increases our depth of capabilities so that we can provide our biotechnology and biopharmaceutical customers with integrated solutions. Doing so enhances their efficiency and productivity across the entire bioproduction workflow.”
Highlights at INTERPHEX include
• New Thermo Scientific bioreactor controller platforms for the Thermo Scientific single-use systems offer the choice, performance and flexibility. Developed with technology integration partners Applikon and Finesse and under the Thermo Scientific brand, the controllers meet the needs of both highly configurable cGMP and cost-effective research applications.
• New Thermo Scientific Sorvall RC BIOS 10 large-capacity centrifuge offers a new 10-L capacity for batch bioprocessing centrifugation. The system combines the centrifuge with carbon fiber rotors and paperless data collection software, to improve productivity and protects sample safety and integrity.
• Life Technologies products that span the biologics workflow and include a portfolio of premium solutions and services focused on upstream cell culture, downstream purification and analytics for detection and quantitation of process/product impurities and contaminants. Products on display include Life Technologies Gibco cell culture media and feeds in both liquid and AGT Dry Media formats, GoPure Prepacked and POROS A, G and CaptureSelect Chromatography Columns, and MycoSEQ Myccoplasma Detection System.
• The industry-leading Thermo Scientific Aegis5-14 Film, the most advanced film for demanding cell culture and single-use bioprocessing applications.
• The Thermo Scientific HyPerforma Single-Use Bioreactor (SUB), which offers all of the advantages of previous SUBs while offering advancements that make it easier to manage tubing systems and loading of single-use Thermo Scientific bioprocess containers. The SUBs also feature faster heat up and cool down, flexible positioning, and height-adjustable single- or dual-filter brackets.
The combination of Thermo Scientific’s single-use and bioprocessing technologies with the cell culture, purification, and analytics business from Life Technologies increases our depth of capabilities so that we can provide our biotechnology and biopharmaceutical customers with integrated solutions across the entire bioproduction workflow.
Related News
-
News Swiss pharma industry warns US tariffs could harm global patient care
The Swiss pharmaceutical sector has raised alarms over new US tariffs on medicines, warning of disrupted supply chains, increased costs, and delayed innovation, all of which could jeopardise patient access to essential treatments worldwide.
-
News Women in Pharma: CPHI India – India’s Pharmaceutical Industry and Gender Inclusion Challenges
India’s pharmaceutical industry has emerged as a significant player in the global market, valued at USD 50 billion in FY 2023-2024, according to Frost & Sullivan’s analysis. This sector encompasses a diverse portfolio, including drugs, vacc... -
News Biogen acquires Apellis Pharmaceuticals to boost immunology and rare disease profile
Biogen Inc. has announced its acquisition of Apellis Pharmaceuticals, Inc., a move that is set to significantly enhance its growth portfolio in immunology and rare diseases. The agreement, valued at approximately US$5.6 billion, will see Biogen purchas... -
News Gilead Sciences acquires Ouro Medicines for over US$2 billion
Gilead Sciences confirms a deal to take over Ouro Medicines, adding to a portfolio of therapies for autoimmune diseases.
-
News Women in Pharma: Advancing Women's Health
Discover the latest innovations in technologies and therapeutics that are revolutionising women's health in our latest CPHI Online Women in Pharma infographic.
-
News CPHI Pharma Awards 2026: Recognising Excellence in an Evolving Industry
Submissions now open — deadline May 16
-
News Dr Reddy's to launch generic semaglutide in India
Dr Reddy’s Laboratories, one of India’s leading pharmaceutical companies, is preparing to launch a generic version of semaglutide, branded as Obeda, in March. Obeda is expected to provide a more affordable alternative to Ozempic a... -
News Frontier Biotech and GSK Forge RNA Therapy Partnership
Frontier Biotechnologies and GSK have entered a global licensing agreement to advance small interfering RNA (siRNA) therapeutics. This collaboration grants GSK exclusive rights to develop and commercialise two promising siRNA candidates, marking a mile...